Business
Oncolytics Biotech(R) to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference
CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 23, 2019 / Oncolytics Biotech ® I...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"Oncolytics Biotech(R) to Present at the 2019 Bloom Burton & Co. Healthcare Investor ConferenceCALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 23, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it would present at the 2019 Bloom Burton & Co. Investor Conference. The presentation, by Dr. Matt Coffey, President & CEO of Oncolytics, will take place at 11:00 am ET, on Tuesday, April 30, 2019, at the Metro Toronto Convention Centre, Toronto, Ontario.A live audio link to the webcast session will be available on the Company's website at http://www.oncolyticsbiotech.com/investor-centre/presentations. It is recommended that listeners log on 10 minutes in advance of the live session to register and download any necessary software. An audio replay will be accessible approximately two hours following the presentation on the Oncolytics website.About Oncolytics Biotech Inc.Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype - turning \"cold\" tumors \"hot\" - through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com. This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements, including the Company's belief as to the potential and mode of action of REOLYSIN, also known as pelareorep, as a cancer therapeutic; and other statements related to anticipated developments in the Company'...